Osteoporosis. Part II. Prevention of bone loss and fractures in women and risks of menopausal estrogen therapy

Academic Article

Abstract

  • As the benefits of postmenopausal estrogen therapy for prophylaxis against osteoporosis become more obvious, reassessment of the risks of such therapy is necessary for a physician to care appropriately for post-menopausal patients. Current data suggest that exogenous estrogen in doses appropriate for prevention of osteoporosis increases the risk of endometrial carcinoma less than was previously thought and does not increase the risk of dying from the disease. Moreover, the increased risk can be abolished by administering progestin. Estrogen therapy does not appear to increase the risk of breast cancer or cardiovascular disease, and there is preliminary evidence that treating women with estrogen may reduce age-specific mortality. To help women make informed decisions about estrogen replacement therapy, a physician must place the well-publicized but often negligible risks of estrogen therapy in proper perspective and balance them against the substantial benefits such therapy provides.
  • Authors

    Published In

    Author List

  • Boushey HA; Warnock DG; Smith LH
  • Start Page

  • 204
  • End Page

  • 211
  • Volume

  • 139
  • Issue

  • 2